Mayne Pharma, Warner Chilcott, Mylan infectious news

Warner Chilcott said the U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction granted by the U.S. District Court for the District of New Jersey prohibiting Mylan from selling a generic version of 150 mg Doryx doxycycline delayed-release tablets. The case was remanded to the district court. According to Warner Chilcott, the appellate court said the district court failed to hold an evidentiary hearing and make "sufficient findings" in regards to Mylan's invalidity claims. In its suit, Mylan said Mayne's U.S. Patent No. 6,958,161 covering Doryx is invalid, unenforceable and/or will not be infringed by the ANDA. The patent expires in 2022. The trial is expected to begin next quarter. ...